Want to see EWTX full AI Analyst Report?
Edgewise Therapeutics (EWTX) Income Statement
Edgewise Therapeutics Income Statement
Last quarter (Q2 2026), Edgewise Therapeutics's total revenue was $0.00. In Q2, Edgewise Therapeutics's net income was $-57.33M. See Edgewise Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ -2.27M | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ 189.14M | $ 158.83M | $ 114.36M | $ 71.66M | $ 43.22M | |
| Depreciation and Amortization | $ 2.27M | $ 2.29M | $ 1.73M | $ 538.00K | $ 272.00K |
| $ -165.53M | $ -131.52M | $ -98.43M | $ -63.08M | $ -42.54M | |
| $ -191.41M | $ -158.83M | $ -114.36M | $ -71.66M | $ -43.22M | |
| $ 23.61M | $ 25.02M | $ 14.19M | $ 4.02M | $ 402.00K | |
| $ -167.79M | $ -133.81M | $ -100.16M | $ -67.64M | $ -42.81M | |
| $ -167.79M | $ -133.81M | $ -100.16M | $ -67.64M | $ -42.81M | |
| Per Share Metrics | |||||
| Basic EPS | $ -1.63 | $ -1.45 | $ -1.57 | $ -1.26 | $ -0.86 |
| Diluted EPS | $ -1.63 | $ -1.45 | $ -1.57 | $ -1.26 | $ -0.86 |
| Weighted Average Shares Outstanding | 102.93M | 92.41M | 63.72M | 53.59M | 49.50M |
| Weighted Average Shares Outstanding (Diluted) | 102.93M | 92.41M | 63.72M | 53.59M | 49.50M |
Currency in USD